Activist fund MAK Capital, led by Michael A. Kaufman, has urged the leadership of German biotech firm Evotec to list its US unit and speed up its cost cutting program after the shares have lost about 85% over the past five years https://t.co/XVN6eVww8m ...

Victoria Fernandez, Chief Market Strategist at Crossmark Global Investments, warns stretched valuations and rate concerns put markets on edge, calling Gilead a smart buy as biotech rebounds. ...

Hi, I'm Charles Roberts, uh, chief investment strategist and head of venture at ARC. Uh, backgroundwise, I was a surgeon, then moved into being a biotech entrepreneur, founded several different biotech companies, including mainly at the intersection between AI and genomics. At ARC, uh, primarily I lead venture where we have a broad deep tech portfolio across private and some public companies.I work on both strategic side and day-to-day operational management leadership of the team and working very closely w ...

Obesity Drug Market & Competition - Amgen's once-monthly weight loss shot, Maritide, showed patients without type 2 diabetes losing an average of 20% of their body weight after one year, but with a high rate of side effects and discontinuations [1] - Eli Lilly appears to be leading the obesity drug race with a safe oral candidate and an injectable (amalin) that provides weight loss with less muscle mass loss [2] - Novo Nordisk is facing challenges with disappointing Kaggarma data, while Eli Lilly is presenting positive results [2] - Novo Nordisk currently holds 33% of the market share, but Eli Lilly's oral data looks promising [4] - The market may not be seeking a 25% weight loss if other options offer around 22% [5] Amgen's Valuation & Pharma Sector - Amgen's stock dropped almost 6% after disappointing results for its weight loss shot [1] - Amgen is trading at approximately 12-13 times next year's numbers, which may not be considered cheap given the current pharma multiples and revenue cliffs [7][8] - The average pharma multiple is around 10 [7] - Over 50% of revenue for companies like Merck and Bristol-Myers Squibb will disappear by the end of the decade [8] Biotech & M&A - Biotech has had a decent run, with potential catalysts for M&A activity [9] - Despite potential asset quality concerns, increased M&A activity is expected in the biotech sector due to revenue degradation at the pharma level [11] - Big Pharma companies need to pursue M&A, with Pfizer, having spent $60 billion since the pandemic, actively seeking more assets, potentially in the obesity area [12]

Market Trends - Crude oil: The company is inclined to fade the spike in crude [1] - Biotech: The company sees a buying opportunity in the biotech space, though not a huge breakout [1] - Industrials: The company believes industrials are worth a lot [1] Investment Opportunities - Biotech: The company suggests a buying opportunity in the biotech space [1] - Industrials: The company highlights the value in industrials [1] - Caterpillar: The company suggests taking a look at Caterpillar [1] Specific Companies - Mike Co: The company acknowledges a fluid situation [1] - Uber: The company mentions Uber court [1] - Caterpillar: The company suggests taking a look at Caterpillar [1]

Crispr Technology & Applications - Crispr 基因编辑技术能够对患者的 DNA 进行精确编辑，从而识别新的治疗靶点并纠正某些疾病，扩大可治疗疾病的范围 [2] - Crispr 技术与 AI 结合，加速识别靶点和疗法，从而加快新疗法上市的速度 [3] - 癌症，尤其是无法以其他方式治疗的儿童疾病和罕见癌症，可能是 Crispr 技术首先产生影响的领域 [5] Regulatory Landscape - FDA 对新的治疗方法和技术平台持支持态度，并倾向于快速批准 [5] - 美国卫生与公众服务部 (HHS) 部长承诺支持细胞和基因治疗领域，这对行业来说是一个巨大的推动力 [7] - 众议院拨款委员会也表达了对细胞和基因治疗领域的支持，释放了积极信号 [7] Manufacturing & Supply Chain - 该公司主要在美国本土进行生产，对进口尤其是来自中国的依赖程度不高 [9] - 公司在马萨诸塞州进行生产，并在匹兹堡进行扩张 [9] - 匹兹堡的团队致力于支持当地学校的 STEM (科学、技术、工程和数学) 项目 [9]